(Press-News.org) SCOTTSDALE, Ariz. — Jan. 22, 2013 — A multi-center Phase III clinical trial demonstrates that Abraxane (nab-paclitaxel) plus gemcitabine is the first combination of cancer drugs to extend survival of late-stage pancreatic cancer patients compared to standard treatment.
The MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study was led by physicians from Scottsdale Healthcare's Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen).
Their findings show that Abraxane plus gemcitabine was well tolerated and resulted in clinically meaningful outcomes compared to gemcitabine alone, the current standard of care. The study abstract was released today and the data will be presented at the American Society of Clinical Oncology (ASCO) 2013 Gastrointestinal Cancers annual meeting Jan. 25 in San Francisco.
"We are ecstatic that this clinical trial of Abraxane plus gemcitabine improves survival for patients with advanced stage IV pancreatic cancer," said Dr. Daniel Von Hoff, international lead investigator for MPACT, chief scientific officer for Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, and TGen's Physician-In-Chief. "It once again demonstrates that laboratory science based medicine can make a difference for patients."
MPACT is the largest phase III clinical trial completed in advanced pancreatic cancer with more than 800 patients. Findings from the study showed a 59 percent increase in one-year median survival rates from less than a quarter of the patients (22 percent) to more than a third (35 percent). The two-year survival rate for this cancer is negligible, less than 4 percent, but that more than doubles (9 percent) with the nab-paclitaxel/gemcitabine combination.
One of those patients was Lynne Jacoby, 48, of Phoenix, who works as a director of compliance for a healthcare company. Jacoby was given only weeks to live when her Stage 4 pancreatic adenocarcinoma, a tumor the size of a golf ball, was first diagnosed in April 2012 — nine months ago.
"If you had to live your life in a year, and that is all the time you have, wouldn't you do everything you could to experience this time," said Jacoby, who for nearly a year before her diagnosis had experienced night sweats, indigestion, stomach pains, neck and back pain, and an elevated white-blood count.
She began the treatment of Abraxane plus gemcitabine in May 2012 and continues on the medications, saying now that she "feels awesome, wonderful." She is scheduled to remain on the drug combination through May 2013.
"Life is priceless. No amount of money can be placed on life. I know I would be gone already if it was not for Dr. Von Hoff," said Jacoby, who also refers to him as "Dr. Von Hope."
The study showed significant improvement among some of the sickest patients including those with increased metastases. Significantly there was no increase in life-threatening toxicity. Other drug combinations that have demonstrated benefit have been limited by increased toxicities.
"This is a major improvement in a cancer with the lowest survival rates among all cancer types," said Dr. Ramesh Ramanathan, medical director of Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare and principal investigator for the clinical trial in the United States. "Advanced pancreatic cancer is fourth most common cause of cancer death in the United States and throughout the world. It is difficult to diagnose with a majority of the cases diagnosed at a late stage after the disease has already advanced."
Abraxane wraps traditional chemotherapy, paclitaxel, in near-nano sized shells of albumin, a protein that the tumor sees as food. The tumor uses various mechanisms to preferentially attract the albumin, which then acts like a "Trojan Horse" to release its package of chemotherapy inside the tumor. It is approved in the U.S. for metastatic breast cancer and non-small cell lung cancer.
The pancreas is a gland behind the stomach that secretes enzymes into the upper part of the small intestine to help digestion. It also produces hormones, including insulin, which helps regulate the metabolism of sugars.
The incidence of pancreatic cancer is increasing worldwide with an estimated 279,000 cases per year, including nearly 44,000 in the U.S. in 2012, and resulting in more than 37,000 American deaths last year.
###
About TGen
The Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. For more information, visit www.tgen.org
Press Contact:
Steve Yozwiak
TGen Senior Science Writer
602-343-8704
syozwiak@tgen.org
END
A few years ago, manufacturers of water bottles, food containers, and baby products had a big problem. A key ingredient of the plastics they used to make their merchandise, an organic compound called bisphenol A, had been linked by scientists to diabetes, asthma and cancer and altered prostate and neurological development. The FDA and state legislatures were considering action to restrict BPA's use, and the public was pressuring retailers to remove BPA-containing items from their shelves.
The industry responded by creating "BPA-free" products, which were made from plastic ...
Technological advancements in medicine have allowed patients suffering from musculoskeletal conditions such as hip and knee pain to regain mobility and live relatively pain-free. But some "high risk" surgical devices that have been approved by the U.S. Food and Drug Administration (FDA) are not required to go through clinical trials, where a product is tested to determine its safety and effectiveness.
"This could be potentially very dangerous. Many Americans – patients and even physicians - are not aware of how many devices in this country are on the market without having ...
A new study published in The Journal of Sexual Medicine reveals that within a nationally representative study of American men and women, sex was rated as highly arousing and pleasurable whether or not condoms and/or lubricants were used. Condoms and lubricants are commonly used by both women and men when they have sex.
Led by Debby Herbenick, PhD, MPH and Michael Reece, PhD, MPH, of the School of Public Health-Bloomington, Indiana University, researchers reviewed a nationally representative study of men and women in the United States ages 18-59 to assess characteristics ...
AUDIO:
An FDA-commissioned study finds that two proposed nutrition labeling changes could potentially make nutritional content information easier to understand. Study participants could more accurately assess the number of calories or...
Click here for more information.
Philadelphia, PA, January 23, 2013 – The Nutrition Facts label was introduced 20 years ago and provides consumers with important information, including: the serving size, the number of servings in the package, the ...
Lung and head and neck cancer patients who smoked before surgery are more likely to relapse than those who had quit before surgery, Moffitt Cancer Center researchers say. They found that smoking-relapse prevention interventions are needed immediately after surgery to help prevent relapse.
The study was published in a recent issue of the journal Cancer.
"Cigarette smoking is responsible for 30 percent of all cancer-related mortalities," said study corresponding author Vani Nath Simmons, Ph.D., assistant member of the Health Outcomes and Behavior Program at Moffitt. "Head ...
For more than fifteen years, Thierry Jamin, French Archaeologist and adventurer, explores the jungles of South Peru in every possible direction, searching for clues of the permanent presence of the Incas in the Amazonian forest, and the legendary lost city of Paititi. After the discovery of about thirty incredible archeological sites, located in the North of the department of Cuzco, between 2009 and 2011, which include several fortresses, burial and ceremonial, centers, and small Inca cities composed by hundreds of buildings, and many streets, passages, squares..., Thierry ...
Rich Von, one of the partners of Von Vesting, Inc., is excited to announce that the company is in high-level talks to take on a $30 million rental fund. If the fund goes through, Rich Von says the company will have achieved part one of its goal to reach $100 million in rental properties.
As Rich Von explains, each $10 million fund represents about 110 single-family residences. The company has always put an emphasis on choosing the best properties for an area, including in its criteria the possibilities of improved economic development of that area. While Rich Von is ...
With a customer satisfaction rating of 4.5 stars in 2012, Gatlinburg Falls Resort has won the prestigious CMUS Talk of the Town Customer Satisfaction Award for the third consecutive year in the Hotels & Travel category.
The Talk of the Town Awards, presented by Talk of the Town News, Customer Care News magazine and Celebration Media U.S. (CMUS), honor companies and professionals that provide excellent customer service as reported by their customers through no-cost, user-review websites, blogs, social networks, business rating services, and other honors and accolades. ...
**Avail Clinical Research is now enrolling for a Type 2 Diabetes Clinical Trial in Florida. To get started, visit Avail Clinical Research or call us directly at (386) 310-1334.
BACKGROUND & RATIONALE
Type 2 diabetes (T2DM) is one of the largest medical burdens in the United States. At present it is estimated that 25.8 million people in the US have diabetes (8.3% of the population) of which 7 million remain undiagnosed. It is projected that the number of people with diabetes will more than double by the year 2050.
Approximately 85% of patients with T2DM are ...
The holidays are over. You and your children are home now, after sharing gifts, meals, and stories with your friends and relatives. Maybe you've had a chance to teach your kids a little about your family, and maybe they'd like to learn more about where you or your relatives came from. Well, there's a fun opportunity for your kids to do just that!
During the holiday break, the "Celebrate America" writing program (sponsored by the American Immigration Council and hosted locally by the law firm De Mott, McChesney, Curtright, and Armendariz) has been accepting ...
